Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CITY THERAPEUTICS, INC.CTY · Entity 184066 | Chief Financial Officer | October 15, 2026 | October 16, 2026 |
| Keros Therapeutics, Inc.KROS · Entity 6242 | CHIEF FINANCIAL OFFICER | February 24, 2026 | February 26, 2026 |
| Wave Life Sciences, Inc.WVE · Entity 4976 | Chief Financial Officer | March 07, 2019 | March 11, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CITY THERAPEUTICS, INC.
Report date October 15, 2026 · Filed October 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.10 · Expires 2036-08-03 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-10-15 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: 25% of the shares underlying this option vest on August 4, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares underlying this option vest on August 4, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
Keros Therapeutics, Inc.
Report date February 24, 2026 · Filed February 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.52 · Expires 2036-02-23 | Direct | 60,000 |
Reported balance
After 2026-02-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-24 · Grant · Acquired 60,000 · Balance 60,000 F1: One-fourth (1/4th) of the shares subject to the option shall vest on February 24, 2027, and the remaining shares subject to the option shall vest in twelve substantially equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: One-fourth (1/4th) of the shares subject to the option shall vest on February 24, 2027, and the remaining shares subject to the option shall vest in twelve substantially equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.
Wave Life Sciences, Inc.
Report date March 07, 2019 · Filed March 11, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 29,186 |
Reported balance
After 2019-03-07 transaction · row 1
1 source rowRow 1 · 2019-03-07 · Grant · Acquired 13,500 · Balance 29,186 F1: Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 15, 2020 through February 15, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 15, 2020 through February 15, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 24, 2026 Filed Feb 26, 2026 21:15 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | GrantEmployee Stock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $15.52 | $0.00 |
DisclosureSEC source: 0001682068-26-000005 · form4-02262026_040214.xml · derivative · entry 1 Regnante Keith · CIK 0001682068 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2036-02-23 F1 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option shall vest on February 24, 2027, and the remaining shares subject to the option shall vest in twelve substantially equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:15 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 4,739 | $16.35 | $77,482.65 |
DisclosureSEC source: 0001682068-26-000003 · form4-02202026_040201.xml · nonDerivative · entry 1 Regnante Keith · CIK 0001682068 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,261 F1 · shares: The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.05 to $16.65 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 18, 2025 Filed Feb 19, 2025 21:15 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | GrantCommon Stock | 44,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004597 · form4-02192025_040209.xml · nonDerivative · entry 1 Regnante Keith · CIK 0001682068 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,000 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs vest as follows: 33% of the RSUs shall vest on February 17, 2026, an additional 34% of the total number of RSUs shall vest on August 15, 2026, and the remaining 33% of the total number of RSUs shall vest on February 16, 2027, in each case, subject to the Reporting Person's Continuous Service (as defined in the 2020 Plan) through each applicable vesting date. Read SEC document |
| February 13, 2024 Filed Feb 16, 2024 01:40 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | GrantEmployee Stock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $56.18 | $0.00 |
DisclosureSEC source: 0001415889-24-004003 · form4-02162024_010256.xml · derivative · entry 1 Regnante Keith · CIK 0001682068 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2034-02-12 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on February 13, 2025, and 6.25% of the shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| January 04, 2024 Filed Jan 8, 2024 21:43 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001209191-24-001155 · doc4.xml · derivative · entry 3 Regnante Keith · CIK 0001682068 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,622 Underlying: Common Stock · 40,000 shares Expires 2030-04-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 8, 2023. F2 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option shall vest on February 24, 2021, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| January 04, 2024 Filed Jan 24, 2025 21:15 UTC Amendment | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 40,000 | $45.29 | $1,811,600.00 |
DisclosureSEC source: 0001415889-25-002024 · form4a-01242025_040104.xml · nonDerivative · entry 2 Regnante Keith · CIK 0001682068 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · date: This amendment is being filed to correct the Date of Earliest Transaction and the Transaction Date of each transaction listed in Table I. F2 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 8, 2023. Read SEC document |
| January 04, 2024 Filed Jan 24, 2025 21:15 UTC Amendment | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionCommon Stock | 40,000 | $16.00 | $640,000.00 |
DisclosureSEC source: 0001415889-25-002024 · form4a-01242025_040104.xml · nonDerivative · entry 1 Regnante Keith · CIK 0001682068 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: This amendment is being filed to correct the Date of Earliest Transaction and the Transaction Date of each transaction listed in Table I. F2 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 8, 2023. Read SEC document |
| November 04, 2023 Filed Jan 8, 2024 21:43 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 40,000 | $45.29 | $1,811,600.00 |
DisclosureSEC source: 0001209191-24-001155 · doc4.xml · nonDerivative · entry 2 Regnante Keith · CIK 0001682068 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 8, 2023. Read SEC document |
| November 04, 2023 Filed Jan 8, 2024 21:43 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionCommon Stock | 40,000 | $16.00 | $640,000.00 |
DisclosureSEC source: 0001209191-24-001155 · doc4.xml · nonDerivative · entry 1 Regnante Keith · CIK 0001682068 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 8, 2023. Read SEC document |
| June 09, 2023 Filed Jun 12, 2023 20:13 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001209191-23-036261 · doc4.xml · derivative · entry 9 Regnante Keith · CIK 0001682068 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 93,622 Underlying: Common Stock · 20,000 shares Expires 2030-04-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 8, 2023. F7 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option shall vest on February 24, 2021, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| June 09, 2023 Filed Jun 12, 2023 20:13 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 2,579 | $47.25 | $121,857.75 |
DisclosureSEC source: 0001209191-23-036261 · doc4.xml · nonDerivative · entry 7 Regnante Keith · CIK 0001682068 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 8, 2023. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.015 to $47.60 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 09, 2023 Filed Jun 12, 2023 20:13 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 1,428 | $46.46 | $66,344.88 |
DisclosureSEC source: 0001209191-23-036261 · doc4.xml · nonDerivative · entry 6 Regnante Keith · CIK 0001682068 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,579 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 8, 2023. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.015 to $47.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 09, 2023 Filed Jun 12, 2023 20:13 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 15,993 | $45.03 | $720,164.79 |
DisclosureSEC source: 0001209191-23-036261 · doc4.xml · nonDerivative · entry 5 Regnante Keith · CIK 0001682068 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,007 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 8, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.995 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 09, 2023 Filed Jun 12, 2023 20:13 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionCommon Stock | 20,000 | $16.00 | $320,000.00 |
DisclosureSEC source: 0001209191-23-036261 · doc4.xml · nonDerivative · entry 4 Regnante Keith · CIK 0001682068 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 8, 2023. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 20:13 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001209191-23-036261 · doc4.xml · derivative · entry 8 Regnante Keith · CIK 0001682068 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 113,622 Underlying: Common Stock · 20,000 shares Expires 2030-04-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 8, 2023. F7 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option shall vest on February 24, 2021, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 20:13 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 2,699 | $48.65 | $131,306.35 |
DisclosureSEC source: 0001209191-23-036261 · doc4.xml · nonDerivative · entry 3 Regnante Keith · CIK 0001682068 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 8, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.12 to $48.935 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 20:13 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 17,301 | $47.66 | $824,565.66 |
DisclosureSEC source: 0001209191-23-036261 · doc4.xml · nonDerivative · entry 2 Regnante Keith · CIK 0001682068 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,699 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 8, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.12 to $48.095 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 20:13 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionCommon Stock | 20,000 | $16.00 | $320,000.00 |
DisclosureSEC source: 0001209191-23-036261 · doc4.xml · nonDerivative · entry 1 Regnante Keith · CIK 0001682068 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 8, 2023. Read SEC document |
| February 16, 2023 Filed Feb 17, 2023 21:14 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | GrantEmployee Stock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $54.38 | $0.00 |
DisclosureSEC source: 0001209191-23-010557 · doc4.xml · derivative · entry 1 Regnante Keith · CIK 0001682068 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2033-02-15 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on February 16, 2024, and 6.25% of the shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| January 21, 2022 Filed Jan 25, 2022 21:15 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | GrantEmployee Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $46.30 | $0.00 |
DisclosureSEC source: 0001209191-22-004767 · doc4.xml · derivative · entry 1 Regnante Keith · CIK 0001682068 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-01-20 F1 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option shall vest on January 19, 2023, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| January 10, 2021 Filed Jan 12, 2021 22:25 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | GrantEmployee Stock Option (right to buy) · Derivative | 49,150 | $0.00 Strike: $70.93 | $0.00 |
DisclosureSEC source: 0001209191-21-003274 · doc4.xml · derivative · entry 1 Regnante Keith · CIK 0001682068 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,150 Underlying: Common Stock · 49,150 shares Expires 2031-01-09 F1 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option shall vest on January 7, 2022, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| April 07, 2020 Filed Apr 9, 2020 01:02 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | GrantEmployee Stock Option (right to buy) · Derivative | 133,622 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001209191-20-023990 · doc4.xml · derivative · entry 2 Regnante Keith · CIK 0001682068 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,622 Underlying: Common Stock · 133,622 shares Expires 2030-04-06 F2 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option shall vest on February 24, 2021, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| April 07, 2020 Filed Apr 9, 2020 01:02 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | GrantEmployee Stock Option (right to buy) · Derivative | 18,430 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001209191-20-023990 · doc4.xml · derivative · entry 1 Regnante Keith · CIK 0001682068 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,430 Underlying: Common Stock · 18,430 shares Expires 2030-04-06 F1 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option shall vest on March 1, 2021, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| March 07, 2019 Filed Mar 11, 2019 23:19 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantOrdinary Shares | 13,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-007114 · doc4.xml · nonDerivative · entry 1 Regnante Keith · CIK 0001682068 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,186 F1 · shares: Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 15, 2020 through February 15, 2023. Read SEC document |
| February 19, 2019 Filed Feb 22, 2019 00:54 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 1,298 | $36.84 | $47,817.80 |
DisclosureSEC source: 0000899243-19-004467 · doc4.xml · nonDerivative · entry 1 Regnante Keith · CIK 0001682068 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,686 F1 · kind: On February 19, 2019, the reporting person sold 1,298 ordinary shares solely to cover taxes associated with the vesting of restricted share units on February 15, 2019. These sales were made pursuant to a 10b5-1 Trading Plan. F2 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $36.83 to $37.4582 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 24, 2018 Filed Sep 26, 2018 22:59 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionShare Option (right to buy) · Derivative | 29,500 | $0.00 Strike: $20.89 | $0.00 |
DisclosureSEC source: 0000899243-18-025320 · doc4.xml · derivative · entry 3 Regnante Keith · CIK 0001682068 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,500 Underlying: Ordinary Shares · 29,500 shares Expires 2026-08-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F2 · derivative.exercise_date: The share option represented a right to purchase a total of 120,000 ordinary shares, 25% of which became exercisable on August 16, 2017, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| September 24, 2018 Filed Sep 26, 2018 22:59 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 29,500 | $55.00 | $1,622,500.00 |
DisclosureSEC source: 0000899243-18-025320 · doc4.xml · nonDerivative · entry 2 Regnante Keith · CIK 0001682068 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,984 F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. Read SEC document |
| September 24, 2018 Filed Sep 26, 2018 22:59 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 29,500 | $20.89 | $616,255.00 |
DisclosureSEC source: 0000899243-18-025320 · doc4.xml · nonDerivative · entry 1 Regnante Keith · CIK 0001682068 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,484 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F2 · price: The share option represented a right to purchase a total of 120,000 ordinary shares, 25% of which became exercisable on August 16, 2017, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| February 16, 2018 Filed Feb 22, 2018 00:16 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 316 | $51.85 | $16,384.60 |
DisclosureSEC source: 0000899243-18-004949 · doc4.xml · nonDerivative · entry 1 Regnante Keith · CIK 0001682068 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,984 F1 · kind: On February 16, 2018, the reporting person sold 316 ordinary shares solely to cover taxes associated with the vesting of restricted share units on February 15, 2018. These sales were made pursuant to a 10b5-1 Trading Plan. F2 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $51.65 to $51.85 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 23, 2018 Filed Jan 26, 2018 01:06 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 26,000 | $0.00 Strike: $40.05 | $0.00 |
DisclosureSEC source: 0000899243-18-002040 · doc4.xml · derivative · entry 2 Regnante Keith · CIK 0001682068 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,000 Underlying: Ordinary Shares · 26,000 shares Expires 2028-01-23 F2 · derivative.exercise_date: The option vests as to 25% of the shares on February 15, 2019 and vests as to an additional 6.25% of the shares quarterly thereafter until February 15, 2022. Read SEC document |
| January 23, 2018 Filed Jan 26, 2018 01:06 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantOrdinary Shares | 13,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-002040 · doc4.xml · nonDerivative · entry 1 Regnante Keith · CIK 0001682068 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,300 F1 · shares: Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 15, 2019, through February 15, 2022. Read SEC document |
| January 25, 2017 Filed Jan 27, 2017 23:14 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 8,600 | $0.00 Strike: $29.05 | $0.00 |
DisclosureSEC source: 0000899243-17-002146 · doc4.xml · derivative · entry 2 Regnante Keith · CIK 0001682068 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,600 Underlying: Ordinary Shares · 8,600 shares Expires 2027-01-25 F2 · derivative.exercise_date: The option vests as to 25% of the shares on February 15, 2018 and vests as to an additional 2.0833% of the shares monthly thereafter until February 15, 2021. Read SEC document |
| January 25, 2017 Filed Jan 27, 2017 23:14 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantOrdinary Shares | 4,300 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-002146 · doc4.xml · nonDerivative · entry 1 Regnante Keith · CIK 0001682068 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,300 F1 · shares: Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 15, 2018, through February 15, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.